BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld MedTech
Home
» PDUFA VI would shift fee burden, listen to patients
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
PDUFA VI would shift fee burden, listen to patients
Aug. 16, 2016
By
Mari Serebrov
No Comments
Combination products. Breakthrough therapies. Sentinel. Biomarkers. And the patient voice. Those were the words buzzing Monday throughout the FDA's public meeting on the PDUFA VI agreement it's reached with industry and patient groups.
BioWorld MedTech